Bristol-Myers Squibb Medical Imaging (BMS-MI) and Amersham Health have signed several strategic agreements involving ultrasound contrast and nuclear medicine. In ultrasound contrast, the firms have signed cross-licensing deals for their respective patent rights.
No licensing fees or royalties will be paid. In addition, both firms have agreed to end patent infringement litigation initiated while North Billerica, MA-based BMS-MI was part of DuPont Pharmaceuticals. Mallinckrodt, Molecular Biosystems, and Sonus Pharmaceuticals have also agreed to discontinue the litigation.
In other new agreements, London-based Amersham Health has extended BMS-MI's right to distribute Amersham's products in Puerto Rico to provide a full range of nuclear medicine products on the island, via BMS-MI's newly acquired local radiopharmacies. In addition, the companies have signed a cross-licensing provision covering radiopharmaceuticals related to angiogenesis.
By AuntMinnie.com staff writersNovember 15, 2001
Related Reading
Amersham renames Nycomed Amersham Imaging, October 15, 2001
Bristol-Myers Squibb completes DuPont purchase, October 4, 2001
DuPont's Definity echoes through contrast market, September 5, 2001
Amersham sales and earnings grow in first half, August 8, 2001
Nycomed Amersham expands ultrasound efforts as Mallinckrodt exits sector, August 6, 2001
Copyright © 2001 AuntMinnie.com
